RT Journal Article SR Electronic T1 Pulmonary rehabilitation in Iranian outpatients with mustard gas lung disease: a randomised controlled trial JF BMJ Open JO BMJ Open FD British Medical Journal Publishing Group SP e083085 DO 10.1136/bmjopen-2023-083085 VO 14 IS 5 A1 Ghanei, Mostafa A1 Philip, Keir E J A1 Moghadam, Mohamed R S A1 Hosseini, Hamed A1 Babaie, Aliakbar A1 Roustanezhad, Mohammad A1 Hopkinson, Nicholas S YR 2024 UL http://bmjopen.bmj.com/content/14/5/e083085.abstract AB Objective People with mustard gas lung disease experience cough, sputum, breathlessness and exercise limitation. We hypothesised that pulmonary rehabilitation (PR) would be beneficial in this condition.Design An assessor-blind, two-armed, parallel-design randomised controlled clinical trial.Setting Secondary care clinics in Iran.Participants 60 men with breathlessness due to respiratory disease caused by documented mustard gas exposure, mean (SD) age 52.7 (4.36) years, MRC dyspnoea score 3.5 (0.7), St. George’s Respiratory Questionnaire (SGRQ) 72.3 (15.2).Interventions Participants were allocated either to a 6-week course of thrice-weekly PR (n=31) or to usual care (n=29), with 6-week data for 28 and 26, respectively.Outcome measures Primary endpoint was change in cycle endurance time at 70% baseline exercise capacity at 6 weeks. Secondary endpoints included 6 min walk distance, quadriceps strength and bulk, body composition and health status. For logistical reasons, blood tests that had been originally planned were not performed and 12-month follow-up was available for only a small proportion.Results At 6 weeks, cycle endurance time increased from 377 (140) s to 787 (343) s with PR vs 495 (171) s to 479 (159) s for usual care, effect size +383 (231) s (p<0.001). PR also improved 6 min walk distance+103.2 m (63.6–142.9) (p<0.001), MRC dyspnoea score −0.36 (−0.65 to −0.07) (p=0.016) and quality of life; SGRQ −8.43 (−13.38 to −3.48) p<0.001, as well as quadriceps strength+9.28 Nm (1.89 to 16.66) p=0.015.Conclusion These data suggest that PR can improve exercise capacity and quality of life in people with breathlessness due to mustard gas lung disease and support the wider provision of this form of care.Trial registration number IRCT2016051127848N1.Data are available on reasonable request. Reasonable requests for study data should be made to the corresponding author.